Form 4 for HALO HALOZYME THERAPEUTICS, INC.
Accepted 2026-09-02 16:59:28 ET · period of report 2026-09-01 · accession 0001159036-26-000117 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-02 16:59 | 2026-09-01 | HALO | Appelhans Dannielle | Dir | A - Grant | $0.00 | +1,161 | 1,161 | New | $0 |
| D | 2026-09-02 16:59 | 2026-09-01 | HALO | Appelhans Dannielle | Dir | A - Grant | $0.00 | +1,778 | 1,778 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Restricted Stock Units | 2026-09-01 | A | A | 1,161 | $0.00 | 1,161 | D | — | — | (F1) Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders. |
| 2 | Derivative | Option to Purchase Common Stock | 2026-09-01 | A | A | 1,778 | $0.00 | 1,778 | D | $107.72 · — to 2036-09-01 | 1,778 Common Stock | (F2) Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders. |